mRNA |
sirolimus:bortezomib (250:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
0.12 |
0.0009 |
mRNA |
Nutlin-3a (-) |
GDSC1000 |
pan-cancer |
AAC |
0.13 |
0.001 |
mRNA |
navitoclax:PLX-4032 (1:1 mol/mol) |
CTRPv2 |
pan-cancer |
AAC |
-0.12 |
0.002 |
mRNA |
TL-2-105 |
GDSC1000 |
pan-cancer |
AAC |
-0.12 |
0.002 |
mRNA |
lapatinib |
gCSI |
pan-cancer |
AAC |
0.19 |
0.002 |
mRNA |
AR-42 |
GDSC1000 |
pan-cancer |
AAC |
-0.11 |
0.003 |
mRNA |
Erlotinib |
gCSI |
pan-cancer |
AAC |
0.19 |
0.003 |
mRNA |
lapatinib |
GDSC1000 |
pan-cancer |
AAC |
0.18 |
0.003 |
mRNA |
Erlotinib |
CCLE |
pan-cancer |
AAC |
0.15 |
0.004 |
mRNA |
GDC-0941 |
gCSI |
pan-cancer |
AAC |
0.2 |
0.004 |